KO Status

RenMab: Antibody Discovery

Drug Information

Drugs in clinical trials: 3
Latest Research Phase: Phase 2 Clinical

Drug Name





Clinical Trials


Phase 2 Clinical

Novartis Pharma Ag

Non-alcoholic Fatty Liver Disease


BIO89-100, TEV-47948

Phase 2 Clinical

Teva, 89bio

Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease

Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical)

Phase 1 Clinical

Anyuan Pharmaceutical Technology (Shanghai) Co Ltd

Non-alcoholic Fatty Liver Disease





Identification of a novel FGF, FGF-21, preferentially expressed in the liver

Nishimura T., Nakatake Y., Konishi M., Itoh N.,

Biochim. Biophys. Acta 1492:203-206(2000)

The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment

Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Gray A.M.,

Genome Res. 13:2265-2270(2003)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Signal peptide prediction based on analysis of experimentally verified cleavage sites

Zhang Z., Henzel W.J.,

Protein Sci. 13:2819-2824(2004)

FGF-21 as a novel metabolic regulator

Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.-S., Mehrbod F., Jaskunas S.R., Shanafelt A.B.,

J. Clin. Invest. 115:1627-1635(2005)

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.,

J. Biol. Chem. 282:26687-26695(2007)

C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors

Wu X., Lemon B., Li X., Gupte J., Weiszmann J., Stevens J., Hawkins N., Shen W., Lindberg R., Chen J.-L., Tian H., Li Y.,

J. Biol. Chem. 283:33304-33309(2008)

Different roles of N- and C- termini in the functional activity of FGF21

Micanovic R., Raches D.W., Dunbar J.D., Driver D.A., Bina H.A., Dickinson C.D., Kharitonenkov A.,

J. Cell. Physiol. 219:227-234(2009)

Fibroblast growth factor signalling: from development to cancer

Turner N., Grose R.,

Nat. Rev. Cancer 10:116-129(2010)